Maxell Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 4.23 M
- Company Age 14 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.61 Cr
- Revenue Growth -28.27%
- Profit Growth -77.07%
- Ebitda -49.04%
- Net Worth 5.39%
- Total Assets -0.03%
About Maxell Pharma
Maxell Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 April 2010 and has a history of 14 years and nine months. Its registered office is in Vellore, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.23 M.
The company currently has active open charges totaling ₹4.61 Cr.
Gnanasekaran Satheeshkumar, Saravanan, Madhuram Chander, and Three other members serve as directors at the Company.
Company Details
-
Location
Vellore, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24297TN2010PTC075380
-
Company No.
075380
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Apr 2010
-
Date of AGM
12 Jan 2024
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Maxell Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shankar Subramanian
|
Managing Director | 16-Apr-2010 | Current |
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Takai Ali
|
Director | 16-Apr-2010 | Current |
|
Gnanasekaran Satheeshkumar
|
Director | 16-Apr-2010 | Current |
|
Saravanan
|
Director | 16-Apr-2010 | Current |
|
Madhuram Chander
|
Director | 16-Apr-2010 | Current |
|
Madhuram Kumar
|
Director | 21-Apr-2022 | Current |
Financial Performance of Maxell Pharma.
Maxell Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 28.27% decrease. The company also saw a substantial fall in profitability, with a 77.07% decrease in profit. The company's net worth moved up by a moderate rise of 5.39%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maxell Pharma?
In 2023, Maxell Pharma had a promoter holding of 52.50% and a public holding of 47.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Royal Castle Property Developers Private LimitedMadhuram Chander and Madhuram Kumar are mutual person
-
Mastro Biologicals Private Limited
Takai Ali is a mutual person
Charges (Loans)
₹46.15 M
₹0
Charges Breakdown by Lending Institutions
- City Union Bank Limited : 2.79 Cr
- Others : 1.82 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Mar 2023 | City Union Bank Limited | ₹2.79 Cr | Open |
| 24 Dec 2021 | Others | ₹1.50 Cr | Open |
| 29 Apr 2021 | Others | ₹3.20 M | Open |
How Many Employees Work at Maxell Pharma?
Unlock and access historical data on people associated with Maxell Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maxell Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maxell Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.